Tell me more


This week's Fierce Biotech is brought to you by QIAGEN.

Trouble viewing? Click here.



Identify potential individuals for clinical trial enrollment faster

Explore how our partnership with Helix advances your NGS CDx strategy in hereditary diseases

Dear Valued Customer,

Did you know that QIAGEN’s global partnership with Helix can help you keep and accelerate your clinical trial timelines in hereditary diseases?

The speed and success of trial recruitment greatly impacts the timelines of your clinical trial. What if you could quickly recruit the right individuals for your trials?

The world-leading population genomics database created by Helix – using its FDA-cleared Exome+® assay – enables you to accurately identify individuals who meet your trial criteria in hereditary diseases. By reducing screening failure rates, you can shorten trial length.

Discover how you can increase the speed of clinical trial enrollment in hereditary diseases.

Tell me more

Best regards,

Your QIAGEN Companion Diagnostics team

Trademarks: QIAGEN®, Sample to Insight® (QIAGEN Group); Exome+® (Helix OpCo, LLC).

Sample to Insight


Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.comor call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017